

**We Claim:**

1. A salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, which is 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate.
  
2. A method of preparing 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate comprising the steps of:
  - a. combining 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and hydrochloric acid in methanol under a nitrogen atmosphere;
  - b. heating the reaction mixture to a temperature ranging from about 42-50<sup>0</sup>C;
  - c. stirring the reaction mixture;
  - d. filtering the reaction mixture while maintaining the temperature above 40<sup>0</sup>C to obtain a clear solution;
  - e. cooling the clear solution to about 30<sup>0</sup>C while stirring under nitrogen atmosphere;
  - f. seeding the solution;
  - g. cooling the seeded solution to about 23<sup>0</sup>C;
  - h. stirring the solution to obtain a suspension;
  - i. cooling the suspension to about -10<sup>0</sup>C;

- j. stirring the suspension;
- k. filtering solids;
- l. rinsing solids with cold methanol; and
- m. drying the solids at about 50-55°C and 10-20 torr to obtain 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate salt.

3. A pharmaceutical composition comprising:

- a) a therapeutically effective amount of a salt as claimed in claim 1; and
- b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.

Dated this 03<sup>rd</sup> day of December, 2007

  
Gitika Suri  
Of Anand and Anand Advocates  
Agents for the Applicants